Overview

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

Status:
RECRUITING
Trial end date:
2029-03-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) 1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison to placebo at week 36.
Phase:
PHASE3
Details
Lead Sponsor:
Debiopharm International SA